Ernexa Therapeutics Inc. Weighted Average Basic Shares Outstanding, Pro Forma
Ernexa Therapeutics Inc. (ERNA) reported Weighted Average Basic Shares Outstanding, Pro Forma of 70.88 thousand shares for the 3-month period ending 2012-09-30, per its 10-Q filed 2012-11-09.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageBasicSharesOutstandingProForma · last filed 2012-11-09
- Ernexa Therapeutics Inc. weighted average basic shares outstanding, pro forma for the quarter ending 2012-09-30 was 70.88K shares, a 17.34% increase year-over-year.
- Ernexa Therapeutics Inc. weighted average basic shares outstanding, pro forma for the quarter ending 2011-09-30 was 60.40K shares.
| Period end | Weighted Average Basic Shares Outstanding, Pro Forma 3 month | Weighted Average Basic Shares Outstanding, Pro Forma 9 month |
|---|---|---|
| 2012-09-30 | 70.88K shares 10-Q · filed 2012-11-09 | 68.54K shares 10-Q · filed 2012-11-09 |
| 2011-09-30 | 60.40K shares 10-Q · filed 2012-11-09 | 60.39K shares 10-Q · filed 2012-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |